Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

Alex Kopelowicz, Roberto Zarate, Konstantinos Tripodis, Veronica Gonzalez, Jim Mintz

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Objective: Atypical antipsychotic medications have generally been found to be more effective than conventional antipsychotics in the treatment of negative symptoms. Whether the benefits derived from the atypical agents are the result of improvements in primary versus secondary negative symptoms is unclear. The authors examined the effects of olanzapine on primary and secondary negative symptoms for patients with severe negative symptoms who did or did not have the deficit syndrome. Method: Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine. Positive and negative symptoms, extra pyramidal side effects, quality of life, and level of functioning of the patients were assessed at baseline and endpoint. Results: All 39 patients completed the 12-week protocol; 13 of the patients had deficit negative symptoms, and 26 had nondeficit negative symptoms. Patients who had nondeficit negative symptoms demonstrated improvements in positive and negative symptoms, level of functioning, and extrapyramidal side effects over baseline. In contrast, patients meeting criteria for the deficit syndrome improved significantly over baseline only in extra pyramidal side effects. Conclusions: The results of this study suggest that olanzapine is efficacious for secondary negative symptoms in schizophrenia but fail to support the contention that olanzapine has a direct beneficial effect on primary negative symptoms.

Original languageEnglish (US)
Pages (from-to)987-993
Number of pages7
JournalAmerican Journal of Psychiatry
Volume157
Issue number6
DOIs
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

olanzapine
Schizophrenia
Antipsychotic Agents
Outpatients
Quality of Life

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. / Kopelowicz, Alex; Zarate, Roberto; Tripodis, Konstantinos; Gonzalez, Veronica; Mintz, Jim.

In: American Journal of Psychiatry, Vol. 157, No. 6, 06.2000, p. 987-993.

Research output: Contribution to journalArticle

Kopelowicz, Alex ; Zarate, Roberto ; Tripodis, Konstantinos ; Gonzalez, Veronica ; Mintz, Jim. / Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. In: American Journal of Psychiatry. 2000 ; Vol. 157, No. 6. pp. 987-993.
@article{5966fccd80b04348a889d5fe18000b9e,
title = "Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia",
abstract = "Objective: Atypical antipsychotic medications have generally been found to be more effective than conventional antipsychotics in the treatment of negative symptoms. Whether the benefits derived from the atypical agents are the result of improvements in primary versus secondary negative symptoms is unclear. The authors examined the effects of olanzapine on primary and secondary negative symptoms for patients with severe negative symptoms who did or did not have the deficit syndrome. Method: Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine. Positive and negative symptoms, extra pyramidal side effects, quality of life, and level of functioning of the patients were assessed at baseline and endpoint. Results: All 39 patients completed the 12-week protocol; 13 of the patients had deficit negative symptoms, and 26 had nondeficit negative symptoms. Patients who had nondeficit negative symptoms demonstrated improvements in positive and negative symptoms, level of functioning, and extrapyramidal side effects over baseline. In contrast, patients meeting criteria for the deficit syndrome improved significantly over baseline only in extra pyramidal side effects. Conclusions: The results of this study suggest that olanzapine is efficacious for secondary negative symptoms in schizophrenia but fail to support the contention that olanzapine has a direct beneficial effect on primary negative symptoms.",
author = "Alex Kopelowicz and Roberto Zarate and Konstantinos Tripodis and Veronica Gonzalez and Jim Mintz",
year = "2000",
month = "6",
doi = "10.1176/appi.ajp.157.6.987",
language = "English (US)",
volume = "157",
pages = "987--993",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "6",

}

TY - JOUR

T1 - Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

AU - Kopelowicz, Alex

AU - Zarate, Roberto

AU - Tripodis, Konstantinos

AU - Gonzalez, Veronica

AU - Mintz, Jim

PY - 2000/6

Y1 - 2000/6

N2 - Objective: Atypical antipsychotic medications have generally been found to be more effective than conventional antipsychotics in the treatment of negative symptoms. Whether the benefits derived from the atypical agents are the result of improvements in primary versus secondary negative symptoms is unclear. The authors examined the effects of olanzapine on primary and secondary negative symptoms for patients with severe negative symptoms who did or did not have the deficit syndrome. Method: Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine. Positive and negative symptoms, extra pyramidal side effects, quality of life, and level of functioning of the patients were assessed at baseline and endpoint. Results: All 39 patients completed the 12-week protocol; 13 of the patients had deficit negative symptoms, and 26 had nondeficit negative symptoms. Patients who had nondeficit negative symptoms demonstrated improvements in positive and negative symptoms, level of functioning, and extrapyramidal side effects over baseline. In contrast, patients meeting criteria for the deficit syndrome improved significantly over baseline only in extra pyramidal side effects. Conclusions: The results of this study suggest that olanzapine is efficacious for secondary negative symptoms in schizophrenia but fail to support the contention that olanzapine has a direct beneficial effect on primary negative symptoms.

AB - Objective: Atypical antipsychotic medications have generally been found to be more effective than conventional antipsychotics in the treatment of negative symptoms. Whether the benefits derived from the atypical agents are the result of improvements in primary versus secondary negative symptoms is unclear. The authors examined the effects of olanzapine on primary and secondary negative symptoms for patients with severe negative symptoms who did or did not have the deficit syndrome. Method: Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine. Positive and negative symptoms, extra pyramidal side effects, quality of life, and level of functioning of the patients were assessed at baseline and endpoint. Results: All 39 patients completed the 12-week protocol; 13 of the patients had deficit negative symptoms, and 26 had nondeficit negative symptoms. Patients who had nondeficit negative symptoms demonstrated improvements in positive and negative symptoms, level of functioning, and extrapyramidal side effects over baseline. In contrast, patients meeting criteria for the deficit syndrome improved significantly over baseline only in extra pyramidal side effects. Conclusions: The results of this study suggest that olanzapine is efficacious for secondary negative symptoms in schizophrenia but fail to support the contention that olanzapine has a direct beneficial effect on primary negative symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0034082008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034082008&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.157.6.987

DO - 10.1176/appi.ajp.157.6.987

M3 - Article

C2 - 10831481

AN - SCOPUS:0034082008

VL - 157

SP - 987

EP - 993

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 6

ER -